Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16674069 | 0.84 | ACHE (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL24735973 | 0.83 | ACHE (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL7523913 | 0.80 | ACHE (0.38) | CHRNB2CHRNA4ACHESMN1; SMN2 | |
| SCHEMBL11924487 | 0.80 | CHRNB2 (0.52) | CHRNB2CHRNA4ACHESMN1; SMN2 | |
| SCHEMBL965762 | 0.79 | — | — | |
| SCHEMBL16673943 | 0.79 | ACHE (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4MEN1 | |
| SCHEMBL9593433 | 0.79 | EGLN1 (0.41) | ACHEALDH1A1 | |
| SCHEMBL22898364 | 0.79 | ACHE (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL31075623 | 0.79 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4ACHE | |
| SCHEMBL28538773 | 0.78 | ACHE (0.36) | CHRNB2CHRNA4ACHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-111566091-A | Novel alkoxyamino derivatives for the treatment of pain and pain related disorders | 埃斯特韦制药有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389035-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOT2 | CHRNB2 381/4885CHRNB4 423/4885CHRNA3 1243/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | CHRNB2 4183/4885CHRNB4 4272/4885CHRNA3 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.